Insider Trading activities of Protalix Biotherapeutics, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protalix Biotherapeutics, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Protalix Biotherapeutics, Inc. since year 2005. Table 2 shows the detailed insider transactions of Protalix Biotherapeutics, Inc. since 2005. The reporting company's ticker symbol is PLX. The reporting company's CIK number is 1006281.
The total value of stock buying since 2005 is $4,257,317.
The total value of stock sales since 2005 is $73,987,303.
The total value of stock option exercises since 2005 is $1,566,833.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Protalix Biotherapeutics, Inc. (PLX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-05 50,000 $40,500 0 $0 0 $0
2016-12 0 $0 7,500,000 $2,377,500 0 $0
2016-09 0 $0 0 $0 122,162 $122
2015-12 10,000 $7,800 0 $0 0 $0
2015-10 4,000,423 $4,060,429 0 $0 0 $0
2014-08 0 $0 8,800,000 $21,736,000 0 $0
2013-08 0 $0 112,330 $569,183 0 $0
2013-03 0 $0 58,333 $336,781 0 $0
2012-05 0 $0 1,042,812 $7,435,249 742,812 $775,981
2010-10 0 $0 140,000 $1,313,550 147,769 $143,631
2010-09 0 $0 120,000 $968,640 120,000 $102,340
2010-08 0 $0 53,027 $371,189 0 $0
2010-06 0 $0 52,973 $370,811 0 $0
2010-04 0 $0 14,000 $98,000 0 $0
2010-03 0 $0 380,000 $2,678,762 0 $0
2009-12 1,680 $14,179 0 $0 0 $0
2009-11 0 $0 1,371,967 $14,241,017 3,384,502 $3,384
2009-10 0 $0 584,238 $5,508,278 509,142 $230,187
2009-09 0 $0 253,074 $1,855,717 0 $0
2009-08 0 $0 1,858,475 $11,533,200 0 $0
2009-07 0 $0 225,000 $1,164,370 122,039 $84,342
2009-05 0 $0 275,000 $956,693 266,687 $78,851
2009-04 0 $0 50,000 $125,933 52,469 $6,296
2009-03 0 $0 56,890 $126,746 39,800 $38,685
2008-10 5,000 $8,185 0 $0 0 $0
2008-05 0 $0 41,427 $113,924 48,370 $19,251
2008-03 10,000 $28,830 0 $0 0 $0
2008-02 0 $0 33,300 $105,760 86,176 $83,763
2007-12 30,000 $97,394 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Protalix Biotherapeutics, Inc. insiders (PLX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-05-16 Manor Moshe (President & CEO) Buy 50,000 .81 40,500
2016-12-02 Camber Capital Management Llc (10% Owner) Sale 5,000,000 .32 1,585,000
2016-09-15 Shaaltiel Yoseph (Executive VP, R&D) Option Ex 122,162 .00 122
2015-12-14 Maimon Yossi (Vice President & CFO) Buy 10,000 .78 7,800
2015-10-19 Camber Capital Management Llc Buy 4,000,423 1.01 4,060,429
2014-08-13 Bio-cell Ltd Sale 4,400,000 2.47 10,868,000
2014-08-13 Bronfeld Zeev Sale 4,400,000 2.47 10,868,000
2013-08-15 Akirov Alfred Sale 2,330 5.07 11,813
2013-08-14 Akirov Alfred Sale 110,000 5.07 557,370
2013-03-12 Akirov Alfred Sale 10,000 5.70 57,000
2013-03-11 Akirov Alfred Sale 18,300 5.74 105,078
2013-03-08 Akirov Alfred Sale 16,898 5.90 99,698
2013-03-07 Akirov Alfred Sale 8,435 5.72 48,248
2013-03-06 Akirov Alfred Sale 4,700 5.69 26,757
2012-05-02 Shaaltiel Yoseph (Executive VP, R&D) Sale 300,000 7.13 2,139,000
2012-05-02 Almon Einat Brill (SVP, Product Development) Sale 166,848 7.13 1,189,626
2012-05-02 Almon Einat Brill (SVP, Product Development) Option Ex 166,848 1.81 302,161
2012-05-02 Maimon Yossi (VP, Chief Financial Officer) Sale 125,964 7.13 898,123
2012-05-02 Maimon Yossi (VP, Chief Financial Officer) Option Ex 125,964 1.81 228,120
2012-05-02 Aviezer David (President & CEO) Sale 450,000 7.13 3,208,500
2012-05-02 Aviezer David (President & CEO) Option Ex 450,000 .55 245,700
2010-10-07 Maimon Yossi (VP, Chief Financial Officer) Sale 70,000 9.67 676,900
2010-10-07 Maimon Yossi (VP, Chief Financial Officer) Option Ex 77,769 .97 75,591
2010-10-06 Almon Einat Brill (VP, Product Development) Sale 15,000 9.29 139,350
2010-10-06 Almon Einat Brill (VP, Product Development) Option Ex 70,000 .97 68,040
2010-10-05 Almon Einat Brill (VP, Product Development) Sale 20,000 9.08 181,600
2010-10-04 Almon Einat Brill (VP, Product Development) Sale 35,000 9.02 315,700
2010-09-07 Almon Einat Brill (VP, Product Development) Sale 22,500 8.16 183,600
2010-09-07 Almon Einat Brill (VP, Product Development) Option Ex 50,000 .69 34,300
2010-09-07 Maimon Yossi (VP, Chief Financial Officer) Sale 31,500 8.16 257,040
2010-09-07 Maimon Yossi (VP, Chief Financial Officer) Option Ex 70,000 .97 68,040
2010-09-03 Almon Einat Brill (VP, Product Development) Sale 27,500 8.00 220,000
2010-09-03 Maimon Yossi (VP, Chief Financial Officer) Sale 38,500 8.00 308,000
2010-08-06 Shaaltiel Yoseph (Executive VP, R&D) Sale 4,619 7.00 32,333
2010-08-05 Shaaltiel Yoseph (Executive VP, R&D) Sale 48,408 7.00 338,856
2010-06-21 Shaaltiel Yoseph (Executive VP, R&D) Sale 52,973 7.00 370,811
2010-04-29 Shaaltiel Yoseph (Executive VP, R&D) Sale 12,691 7.00 88,837
2010-04-14 Shaaltiel Yoseph (Executive VP, R&D) Sale 1,309 7.00 9,163
2010-03-25 Shaaltiel Yoseph (Executive VP, R&D) Sale 50,000 7.00 350,000
2010-03-24 Shaaltiel Yoseph (Executive VP, R&D) Sale 202,700 7.08 1,435,116
2010-03-23 Shaaltiel Yoseph (Executive VP, R&D) Sale 127,300 7.02 893,646
2009-12-02 Bar-shalev Amos (Director) Buy 1,680 8.44 14,179
2009-11-12 Hurvitz Eli (Director) Sale 1,371,967 10.38 14,241,017
2009-11-12 Hurvitz Eli (Director) Option Ex 3,384,502 .00 3,384
2009-10-21 Aviezer David (CEO and President) Sale 34,238 9.36 320,467
2009-10-21 Aviezer David (CEO and President) Option Ex 247,490 .12 29,698
2009-10-20 Aviezer David (CEO and President) Sale 60,000 9.45 567,000
2009-10-19 Shaaltiel Yoseph (Executive VP, R&D) Sale 43,120 9.43 406,621
2009-10-19 Almon Einat Brill (VP, Product Development) Sale 38,320 9.43 361,357
2009-10-19 Almon Einat Brill (VP, Product Development) Option Ex 93,954 .40 37,487
2009-10-19 Aviezer David (CEO and President) Sale 150,000 9.43 1,414,500
2009-10-16 Shaaltiel Yoseph (Executive VP, R&D) Sale 25,680 9.39 241,135
2009-10-16 Almon Einat Brill (VP, Product Development) Sale 23,680 9.39 222,355
2009-10-16 Maimon Yossi (VP, Chief Financial Officer) Sale 40,300 9.35 376,805
2009-10-16 Maimon Yossi (VP, Chief Financial Officer) Option Ex 167,698 .97 163,002
2009-10-15 Shaaltiel Yoseph (Executive VP, R&D) Sale 31,200 9.39 292,968
2009-10-15 Almon Einat Brill (VP, Product Development) Sale 28,000 9.39 262,920
2009-10-15 Maimon Yossi (VP, Chief Financial Officer) Sale 109,700 9.50 1,042,150
2009-09-10 Frost Gamma Investments Trust (10% Owner) Sale 128,074 7.45 954,407
2009-09-09 Frost Gamma Investments Trust (10% Owner) Sale 50,000 7.57 378,500
2009-09-03 Frost Gamma Investments Trust (10% Owner) Sale 15,000 7.21 108,150
2009-09-01 Frost Gamma Investments Trust (10% Owner) Sale 60,000 6.91 414,660
2009-08-28 Frost Gamma Investments Trust (10% Owner) Sale 27,307 6.01 164,115
2009-08-27 Frost Gamma Investments Trust (10% Owner) Sale 40,000 6.04 241,400
2009-08-26 Frost Gamma Investments Trust (10% Owner) Sale 50,000 6.11 305,600
2009-08-25 Frost Gamma Investments Trust (10% Owner) Sale 388,000 6.25 2,371,533
2009-08-24 Frost Gamma Investments Trust (10% Owner) Sale 148,365 6.09 903,691
2009-08-21 Frost Gamma Investments Trust (10% Owner) Sale 15,000 6.09 91,350
2009-08-20 Frost Gamma Investments Trust (10% Owner) Sale 100,000 6.10 610,100
2009-08-19 Frost Gamma Investments Trust (10% Owner) Sale 100,000 6.12 612,500
2009-08-18 Frost Gamma Investments Trust (10% Owner) Sale 76,989 6.13 472,327
2009-08-17 Frost Gamma Investments Trust (10% Owner) Sale 231,952 6.38 1,481,013
2009-08-13 Frost Gamma Investments Trust (10% Owner) Sale 150,000 6.03 904,500
2009-08-12 Frost Gamma Investments Trust (10% Owner) Sale 150,000 6.17 926,250
2009-08-11 Frost Gamma Investments Trust (10% Owner) Sale 26,695 6.06 161,718
2009-08-10 Frost Gamma Investments Trust (10% Owner) Sale 120,000 6.27 742,886
2009-08-07 Frost Gamma Investments Trust (10% Owner) Sale 15,000 6.45 96,750
2009-08-06 Frost Gamma Investments Trust (10% Owner) Sale 4,340 6.80 29,512
2009-08-05 Frost Gamma Investments Trust (10% Owner) Sale 35,950 6.88 247,228
2009-08-04 Frost Gamma Investments Trust (10% Owner) Sale 71,934 7.10 510,947
2009-07-24 Frost Gamma Investments Trust (10% Owner) Sale 20,000 6.25 124,900
2009-07-07 Almon Einat Brill (VP, Product Development) Sale 11,000 4.95 54,450
2009-07-07 Almon Einat Brill (VP, Product Development) Option Ex 59,822 .40 23,868
2009-07-07 Maimon Yossi (VP, Chief Financial Officer) Sale 10,000 5.01 50,100
2009-07-07 Maimon Yossi (VP, Chief Financial Officer) Option Ex 62,217 .97 60,474
2009-07-06 Shaaltiel Yoseph (Executive VP, R&D) Sale 100,000 5.04 504,000
2009-07-06 Almon Einat Brill (VP, Product Development) Sale 44,000 5.13 225,720
2009-07-06 Maimon Yossi (VP, Chief Financial Officer) Sale 40,000 5.13 205,200
2009-05-18 Almon Einat Brill (VP, Product Development) Sale 40,000 4.00 160,000
2009-05-18 Almon Einat Brill (VP, Product Development) Option Ex 44,707 .40 17,838
2009-05-18 Maimon Yossi (VP, Chief Financial Officer) Sale 30,000 4.00 120,000
2009-05-18 Maimon Yossi (VP, Chief Financial Officer) Option Ex 40,348 .97 39,218
2009-05-14 Shaaltiel Yoseph (Executive VP, R&D) Sale 10,000 3.85 38,500
2009-05-13 Shaaltiel Yoseph (Executive VP, R&D) Sale 20,000 3.51 70,200
2009-05-12 Aviezer David (President & CEO) Sale 55,900 3.41 190,619
2009-05-12 Aviezer David (President & CEO) Option Ex 103,571 .12 12,428
2009-05-11 Aviezer David (President & CEO) Sale 38,900 3.41 132,649
2009-05-08 Aviezer David (President & CEO) Sale 5,200 3.40 17,680
2009-05-06 Aviezer David (President & CEO) Sale 20,000 3.01 60,199
2009-05-06 Aviezer David (President & CEO) Option Ex 78,061 .12 9,367
2009-05-05 Aviezer David (President & CEO) Sale 21,600 3.07 66,312
2009-05-04 Aviezer David (President & CEO) Sale 33,400 3.01 100,534
2009-04-20 Aviezer David (President & CEO) Sale 33,300 2.51 83,583
2009-04-20 Aviezer David (President & CEO) Option Ex 52,469 .12 6,296
2009-04-17 Aviezer David (President & CEO) Sale 10,000 2.56 25,600
2009-04-16 Aviezer David (President & CEO) Sale 6,700 2.50 16,750
2009-03-13 Shaaltiel Yoseph (Executive VP, R&D) Sale 8,300 2.18 18,094
2009-03-13 Maimon Yossi (VP, Chief Financial Officer) Sale 7,500 2.23 16,725
2009-03-13 Maimon Yossi (VP, Chief Financial Officer) Option Ex 39,800 .97 38,685
2009-03-12 Maimon Yossi (VP, Chief Financial Officer) Sale 32,241 2.22 71,575
2009-03-11 Maimon Yossi (VP, Chief Financial Officer) Sale 8,849 2.30 20,352
2008-10-10 Frost Gamma Investments Trust (10% Owner) Buy 5,000 1.64 8,185
2008-05-12 Almon Einat Brill (VP, Product Development) Sale 41,427 2.75 113,924
2008-05-11 Almon Einat Brill (VP, Product Development) Option Ex 48,370 .40 19,251
2008-03-11 Frost Gamma Investment Trust (10% Owner) Buy 10,000 2.88 28,830
2008-02-25 Yossi Maimon (VP, Chief Financial Officer) Sale 33,300 3.18 105,760
2008-02-22 Yossi Maimon (VP, Chief Financial Officer) Option Ex 86,176 .97 83,763
2007-12-19 Shaaltiel Yoseph (Executive VP, R&D) Buy 4,800 3.40 16,320
2007-12-18 Shaaltiel Yoseph (Executive VP, R&D) Buy 5,100 3.38 17,212
2007-12-17 Shaaltiel Yoseph (Executive VP, R&D) Buy 5,000 3.35 16,750
2007-12-05 Shaaltiel Yoseph (Executive VP, R&D) Buy 15,100 3.12 47,112

Insider trading activities including stock purchases, stock sales, and option exercises of PLX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Protalix Biotherapeutics, Inc. (symbol PLX, CIK number 1006281) see the Securities and Exchange Commission (SEC) website.